BeOne Medicines (NASDAQ:ONC) CEO Sells $3,489,981.32 in Stock

Posted by Stanley Muller on Jul 17th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 11,698 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32. Following the completion of the transaction, the chief executive officer owned 11,698 shares in the company, valued at approximately $3,489,981.32. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95.
On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Up 2.0%

Shares of ONC stock opened at $317.42 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The firm’s 50 day moving average price is $290.21 and its two-hundred day moving average price is $308.93. The stock has a market cap of $34.83 billion, a price-to-earnings ratio of 71.01 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. On average, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ONC shares. Leerink Partners increased their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Citizens Jmp restated a “market outperform” rating and set a $396.00 price objective on shares of BeOne Medicines in a research note on Wednesday, July 1st. Wolfe Research began coverage on BeOne Medicines in a research report on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price for the company. Guggenheim increased their target price on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada raised their target price on BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $390.92.

Get Our Latest Report on ONC

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ONC. EFG International AG acquired a new stake in BeOne Medicines during the 4th quarter valued at $25,000. Leonteq Securities AG purchased a new position in BeOne Medicines in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines in the 2nd quarter valued at about $35,000. CWM LLC boosted its position in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines during the fourth quarter valued at about $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.